Date: 2012-01-09
Type of information:
Compound: defibrotide
Company: Gentium (Italy) Swedish Orphan Biovitrum (Sweden)
Therapeutic area: Digestive diseases
Type agreement: distribution
Action mechanism:
Disease: prevention and treatment of hepatic veno-occlusive disease (VOD)
Details: Gentium has announced the appointment of the Swedish Orphan Biovitrum (Sobi) as the exclusive distributor of Defibrotide in the following territories: Sweden, Denmark, Norway, Iceland, Finland, Latvia, Lithuania and Estonia.
Under the terms of the agreement, which is valid for 10 years, Sobi will be responsible for managing named-patient requests and achieving price and reimbursement approvals in these territories. Following regulatory approval to market Defibrotide, if any, Sobi will be responsible for sales, marketing and local medical affairs activities in the territories.
Financial terms:
Latest news:
